Neurocrine Biosciences, Inc. (NBIX)
| Previous close | 137.54 |
| Open | 140.18 |
| Bid | 129.23 x 200 |
| Ask | 150.23 x 200 |
| Day's range | 136.01 - 142.36 |
| 52-week range | 89.04 - 148.37 |
| Volume | |
| Avg. volume | 888,567 |
| Market cap | 14.1B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 56.76 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | N/A |
- Investor's Business Daily
No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win
Neurocrine stock jumped early Wednesday after the company's biggest moneymaker, Ingrezza, topped first-quarter sales forecasts.
- Zacks
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -59.62% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Reuters
UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval
The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the company said on Tuesday. Huntington's disease is an inherited condition that causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in motor control, cognition and mental stability. Ingrezza was first approved in 2017 in its oral capsule formulation to treat adults with movement disorders tardive dyskinesia and chorea.
